Get the Stockscreener App
9.3491
2.74%
0.2291
Novavax Inc stock is traded at $9.3491, with a volume of 1.78M.
It is up +2.74% in the last 24 hours and down -31.15% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
See More
Previous Close:
$9.12
Open:
$9
24h Volume:
1.78M
Relative Volume:
0.30
Market Cap:
$1.48B
Revenue:
$793.74M
Net Income/Loss:
$-398.71M
P/E Ratio:
-1.2878
EPS:
-7.26
Net Cash Flow:
$-514.43M
1W Performance:
-6.95%
1M Performance:
-31.15%
6M Performance:
+90.06%
1Y Performance:
+32.72%
1-Day Range:
$8.86
$9.3905
1-Week Range:
$8.86
$10.07
52-Week Range:
$3.5324
$23.86
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Dow Up Almost 300 Points as Voters Rush to Polls - Schaeffers Research
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024 - StockTitan
Novavax appoints new General Manager for Swedish site in Uppsala - Marketscreener.com
Åsa Manelius Named Managing Director of Novavax AB Site - PR Newswire
Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Novavax's vaccine was 96 percent effective in late-stage testing, as well as 86 percent effective against the British variant of COVID-19 - Telegrafi
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock - Yahoo Finance
Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Is Novavax Stock A Sell After An Unexpected Side Effect Torpedoed Its Testing Plans? - Investor's Business Daily
Novavax Q3 Earnings A Week AwayTime To Accept A New Reality (NASDAQ:NVAX) - Seeking Alpha
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Noteworthy Wednesday Option Activity: NVAX, MRK, INOD - Nasdaq
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Novavax (NVAX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Novavax, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
(NVAX) Trading Report - Stock Traders Daily
NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Novavax, Inc. and Encourages Investors to Contact the Firm - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Novavax, Inc. (NVAX) And Encourages Investors to Connect - AccessWire
Novavax gets EU authorization for updated COVID-19 vaccine - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc.NVAX - PR Newswire
Novavax’s COVID-19 vaccine now available for all 194 WHO members - Maryland Daily Record
Novavax’s updated COVID-19 vaccine receives positive opinion in EU - Maryland Daily Record
Novavax: CDC approval for 2nd dose of Covid vaccine - Marketscreener.com
Novavax Inc. stock outperforms competitors despite losses on the day - MarketWatch
Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note - MSN
NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Novavax, Inc. (NVAX) Stockholders to Inquire about Securities Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Novavax, Inc. (NVAX) and Encourages Investors to Learn More About the Investigation - AccessWire
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now? - MSN
This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip? - sharewise
2024-10-21 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Novavax, Inc. (NVAX) And Encourages Investors to Reach Out | NDAQ:NVAX | Press Release - Stockhouse Publishing
Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold - MSN
How Bad Is This News for Novavax? - sharewise
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Novavax, Inc. (NVAX) And Encourages Stockholders to Reach Out - AccessWire
2024-10-20 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Novavax, Inc. (NVAX) And Encourages Stockholders to Reach Out | NDAQ:NVAX | Press Release - Stockhouse Publishing
Novavax Plans to Cut Costs by Another $300 Million - MSN
Novavax, Inc. (NASDAQ:NVAX) Stock Position Lifted by Vontobel Holding Ltd. - MarketBeat
Novavax (NVAX) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Novavax Stock Tumbles 20% After FDA Pauses Clinical Trial On Security Concerns - Barron's
Novavax reports FDA placed clinical hold on IND for COVID-flu combo vaccine - Yahoo Finance
Nigeria rolls out new Oxford R21 malaria vaccine - Marketscreener.com
Trading (NVAX) With Integrated Risk Controls - Stock Traders Daily
Robinhood, Novavax, Phunware, Lucid Group, And Tesla: Why These 5 Stocks Are On Investors' Radars Today - MSN
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novavax Inc Stock (NVAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Trizzino John | EVP, CCO and CBO |
Aug 19 '24 |
Option Exercise |
0.00 |
655 |
0 |
28,627 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Aug 16 '24 |
Option Exercise |
12.96 |
2,367 |
30,676 |
15,652 |
| YOUNG JAMES F | Director |
Jun 21 '24 |
Sale |
14.09 |
7,500 |
105,675 |
61,760 |
| YOUNG JAMES F | Director |
Jun 18 '24 |
Sale |
13.72 |
7,500 |
102,881 |
69,260 |
| Dubovsky Filip | President, R&D |
Jun 17 '24 |
Option Exercise |
6.18 |
13,904 |
85,911 |
80,517 |
| Dubovsky Filip | President, R&D |
Jun 17 '24 |
Sale |
14.47 |
13,904 |
201,164 |
66,613 |
| MCGLYNN MARGARET G | Director |
Jun 12 '24 |
Option Exercise |
0.00 |
6,670 |
0 |
10,470 |
| Alton Gregg H | Director |
Jun 12 '24 |
Option Exercise |
0.00 |
6,670 |
0 |
10,470 |
| DOUGLAS RICHARD | Director |
Jun 12 '24 |
Option Exercise |
0.00 |
6,670 |
0 |
43,920 |
| King Rachel K. | Director |
Jun 12 '24 |
Option Exercise |
0.00 |
6,670 |
0 |
18,920 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):